A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
Price : $35 *
At a glance
- Drugs Aliskiren (Primary) ; Enalapril
- Indications Hypertension
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 11 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jul 2014 According to their ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Aug 2015.